Of note, FLCN deletion in DCs rendered mice unresponsive to the beneficial anti-tumour effect of glutamine supplementation (Fig. 3i), indicating a requirement for FLCN expression in DCs in mediating this therapeutic effect. This evidence concerns the gene FLCN and neoplasm.